Attachment A RFQ 36C252-21-AQ-0571 - Milwaukee and Tomah.xlsx
XLSX spreadsheet 33 KB Posted
- Solicitation number
- 36C25221Q0571
View the file
Other files
| File | Type | Posted |
|---|---|---|
| 36C25221Q0571.docx | DOCX document |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Mil and Tom Base plus 4
| Milwaukee & Tomah VAMC PRICING SCHEDULE | Ordering Period 1 | Ordering Period 2 | Ordering Period 3 | Ordering Period 4 | Ordering Period 5 | Yearly Usage | |||||||||||
| Description | 10/1/21 - 9/30/22 | 10/1/22 - 9/30/23 | 10/1/23 - 9/30/24 | 10/1/24 - 9/30/25 | 10/1/25 - 9/30/26 | Tomah | Milwaukee | ||||||||||
| Allogeneic Components and Product Modifications: | Qty | Unit Price | Estimated Total | Qty | Unit Price | Estimated Total | Qty | Unit Price | Estimated Total | Qty | Unit Price | Estimated Total | Qty | Unit Price | Estimated Total | Qty | Qty |
| Leukoreduced Red Blood Cells | 1700 | $ - 0 | 1700 | $ - 0 | $ - 0 | 1700 | $ - 0 | 1700 | $ - 0 | 1700 | $ - 0 | 100 | 1600 | ||||
| Fresh Frozen Plasma | 264 | $ - 0 | 264 | $ - 0 | 264 | $ - 0 | 264 | $ - 0 | 264 | $ - 0 | 4 | 260 | |||||
| Apheresis Platelets | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Pathogen Reduced Platelet Apheresis | 332 | $ - 0 | 332 | $ - 0 | 332 | $ - 0 | 332 | $ - 0 | 332 | $ - 0 | 2 | 330 | |||||
| Large Volume Delayed Sampling Platelet Apheresis | 12 | $ - 0 | 12 | $ - 0 | 12 | $ - 0 | 12 | $ - 0 | 12 | $ - 0 | 2 | 10 | |||||
| Variable Content Platelet Apheresis | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Cryopreciptate, Random | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Cryopreciptate, Pooled | 51 | $ - 0 | 51 | $ - 0 | 51 | $ - 0 | 51 | $ - 0 | 51 | $ - 0 | 1 | 50 | |||||
| Whole Blood | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Leukoreduced Whole Blood | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Liquid Plasma | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Cryoprecipitate Reduced Plasma (Cryo-poor) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Granulocytes | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| COVID19 Convalescent Plasma (CCP) **** | 31 | $ - 0 | 31 | $ - 0 | 31 | $ - 0 | 31 | $ - 0 | 31 | $ - 0 | 1 | 30 | |||||
| LRBCD (Pediatric Red Cell Set): 3/set | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| LRBCD (Pediatric Red Cell Set): 6/set | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| LRBCD (Pediatric Red Cell Set): 9/set | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| LSDPN (Neonate Platelet Aliquot): Single Unit | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| FFPD (Pediatric Fresh Frozen Plasma Set): 6/set | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Attached Empty Pediatric Bag Set: 3/set | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Attached Empty Pediatric Bag Set: 6/set | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Attached Empty Pediatric Bag Set: 9/set | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Irradiation (per unit) | 162 | $ - 0 | 162 | $ - 0 | 162 | $ - 0 | 162 | $ - 0 | 162 | $ - 0 | 2 | 160 | |||||
| CMV Screening (per unit) | 4 | $ - 0 | 4 | $ - 0 | 4 | $ - 0 | 4 | $ - 0 | 4 | $ - 0 | 1 | 3 | |||||
| HLA Matching (per unit) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| HPA Matching (per unit) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Volume reduction (per unit) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Washing (per unit) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Divided (per unit) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Deglycerized (per unit) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Restocking Fee | 145 | $ - 0 | 145 | $ - 0 | 145 | $ - 0 | 145 | $ - 0 | 145 | $ - 0 | 140 | 5 | |||||
| Autologous Donation Surcharge | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Directed Donation Surcharge | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Blood Import Fee | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 |
ESTIMATED TOTAL $ - 0 $ - 0 $ - 0 $ - 0 $ - 0
****Current rate, but could change due to instructions from FDA and BARDA
| ROUTINE/ASAP ORDER OVERAGE FEES | ||
| TOMAH | 2 | $ - 0 |
| MILWAUKEE | 25 | $ - 0 |
| ESTIMATED TOTAL | $ - 0 |
| STAT ORDER OVERAGE FEES | ||
| TOMAH | 1 | $ - 0 |
| MILWAUKEE | 40 | $ - 0 |
| ESTIMATED TOTAL | $ - 0 |
AFTER HOURS STAT (weekends, holidays, and Monday – Friday from 10pm-6am) misc
| Milwaukee & Tomah VAMC PRICING SCHEDULE | Ordering Period 1 | Ordering Period 2 | Ordering Period 3 | Ordering Period 4 | Ordering Period 5 | Yearly Usage | |||||||||||
| 10/1/21 - 9/30/22 | 10/1/22 - 9/30/23 | 10/1/23 - 9/30/24 | 10/1/24 - 9/30/25 | 10/1/25 - 9/30/26 | Tomah | Milwaukee | |||||||||||
| Additional ancillary transfusion reference processing and testing services listed below | Total | Unit Price | Estimated Total | Total | Unit Price | Estimated Total | Total | Unit Price | Estimated Total | Total | Unit Price | Estimated Total | Total | Unit Price | Estimated Total | Qty | Qty |
| ABO and Rh | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 5 | 10 | |||||
| ABO Antibody Titer | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| ADAMTS13 Activity | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| ADAMTS13 Antibody | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| ADAMTS13 Inhibitor | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| ADAMTS13 Sequence Analysis | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Alloadsorption (per adsorption) | 3 | $ - 0 | 3 | $ - 0 | 3 | $ - 0 | 3 | $ - 0 | 3 | $ - 0 | 1 | 2 | |||||
| Antibody Adsorption RESt/WARM | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Antibody Identification Panel - Saline IAT | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 5 | 10 | |||||
| Antibody Identification Panel - PEG IAT | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 5 | 10 | |||||
| Antibody Identification Panel - LISS IAT | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 5 | 10 | |||||
| Antibody Identification Panel - GEL IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Antibody Identification Panel - Prewarm IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Antibody Identification Panel - Ficin IAT | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 5 | 10 | |||||
| Antibody Identification Panel - DTT/AET IAT | 3 | $ - 0 | 3 | $ - 0 | 3 | $ - 0 | 3 | $ - 0 | 3 | $ - 0 | 1 | 2 | |||||
| Antibody Identification Panel - Chlorquine/EGA IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Antigen Query - 1 Antigen (C,E, or K) | 8 | $ - 0 | 8 | $ - 0 | 8 | $ - 0 | 8 | $ - 0 | 8 | $ - 0 | 1 | 7 | |||||
| Antigen Query - 1 Antigen (all others) | 8 | $ - 0 | 8 | $ - 0 | 8 | $ - 0 | 8 | $ - 0 | 8 | $ - 0 | 1 | 7 | |||||
| Antigen Query - 2 Antigens | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Antigen Query - 3 Antigens | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Antigen Query - 4 Antigens | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Antibody Screen - Saline IAT | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 5 | 10 | |||||
| Antibody Screen - PEG IAT | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 5 | 10 | |||||
| Antibody Screen - LISS IAT | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 5 | 10 | |||||
| Antibody Screen - GEL IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Antibody Screen -Prewarm IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Antibody Screen - Ficin IAT | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 5 | 10 | |||||
| Antibody Screen - DTT/AET IAT | 3 | $ - 0 | 3 | $ - 0 | 3 | $ - 0 | 3 | $ - 0 | 3 | $ - 0 | 1 | 2 | |||||
| Antibody Screen - Chlorquine/EGA IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Antibody Titration | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Antigen Typing (other than Rh) | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 5 | 10 | |||||
| Antigen Typing (Rare) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Autoadsorption - ZZAP (per adsorption) | 7 | $ - 0 | 7 | $ - 0 | 7 | $ - 0 | 7 | $ - 0 | 7 | $ - 0 | 2 | 5 | |||||
| Cell Seperation: Hypotonic Wash | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Cell Seperation: Reticulocyte Preperation | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Chemical Treatment of Serum (2-Mercaptoethanol Treated Serum) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Cold Agglutinin Panel | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Compatibility Screen (Crossmatch) | 6 | $ - 0 | 6 | $ - 0 | 6 | $ - 0 | 6 | $ - 0 | 6 | $ - 0 | 4 | 2 | |||||
| Compatiblity Screen with Alloadsorbed Serum | 6 | $ - 0 | 6 | $ - 0 | 6 | $ - 0 | 6 | $ - 0 | 6 | $ - 0 | 4 | 2 | |||||
| D Antigen Typing | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| DAT Negative Hemolytic Anemia Evaluation | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Direct Antiglobulin Test - Polyreactive AHG | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 5 | 10 | |||||
| Direct Antiglobulin Test - Monospecific Evaluation | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 5 | 10 | |||||
| Direct Antiglobulin Test IgA Detection | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Donath Landsteiner | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Drug Dependent RBC Antibody Study | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Elution (per elution) | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 15 | $ - 0 | 5 | 10 | |||||
| Heparin-Induced Thrombocytopenia Evaluation: PF4 | 6 | $ - 0 | 6 | $ - 0 | 6 | $ - 0 | 6 | $ - 0 | 6 | $ - 0 | 1 | 5 | |||||
| Heparin-Induced Thombocytopenia Evaluation: Serotonin Release Assay | 3 | $ - 0 | 3 | $ - 0 | 3 | $ - 0 | 3 | $ - 0 | 3 | $ - 0 | 1 | 2 | |||||
| HLA Antibody Identification Class I High Resolution | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| HLA Antibody Low Resolution | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| HLA Antibody Screen | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Neutralization | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Neutrophil Antibody | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Partial RhD Anaylsis (molecular) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Partial RhD Screening (serology) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Platelet Crossmatch | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Platelet Antigen Genotyping | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Platelet Transfusion Refractory (PTR) Panel | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Post Transfusion Purpura (PTP) Panel | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Rare Cell Rule Out Panel | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Red Cell Rule-Out Panel (any method) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Red Cell Genotyping Panel (44 antigens) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Red Cell Genotyping STAT Panel (24 antigens) | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Rh Phenotype (D,C,E,c,e) | 6 | $ - 0 | 6 | $ - 0 | 6 | $ - 0 | 6 | $ - 0 | 6 | $ - 0 | 5 | 1 | |||||
| Screen Units: 1 Antigen Screened Unit | 12 | $ - 0 | 12 | $ - 0 | 12 | $ - 0 | 12 | $ - 0 | 12 | $ - 0 | 2 | 10 | |||||
| Screen Units: 2 Antigen Screened Unit | 17 | $ - 0 | 17 | $ - 0 | 17 | $ - 0 | 17 | $ - 0 | 17 | $ - 0 | 2 | 15 | |||||
| Screen Units: 3 Antigen Screened Unit | 12 | $ - 0 | 12 | $ - 0 | 12 | $ - 0 | 12 | $ - 0 | 12 | $ - 0 | 2 | 10 | |||||
| Screen Units: 4 Antigen Screened Unit | 12 | $ - 0 | 12 | $ - 0 | 12 | $ - 0 | 12 | $ - 0 | 12 | $ - 0 | 2 | 10 | |||||
| Screen Units: 5 Antigen Screened Unit | 5 | $ - 0 | 5 | $ - 0 | 5 | $ - 0 | 5 | $ - 0 | 5 | $ - 0 | 1 | 4 | |||||
| Screen Units: 6 Antigen Screened Unit | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Screen Units: 7 Antigen Screened Unit | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Screen Units: 8 Antigen Screened Unit | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Screen Units: 9 Antigen Screened Unit | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Screen Units: 10 or more Antigen Screened Unit | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Screened Unit - Hemoglobin S | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Screened Unit - Molecular | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Screened Unit - Rare Antigen | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Rule-Out Panel - Saline IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Rule-Out Panel - PEG IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Rule-Out Panel - LISS IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Rule-Out Panel - GEL IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Rule-Out Panel - Prewarm IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Rule-Out Panel - Ficin IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Rule-Out Panel - DTT/AET IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Rule-Out Panel - Chlorquie/EGA IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Screen - Saline IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Screen - PEG IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Screen - LISS IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Screen - GEL IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Screen - Prewarm IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Screen - Ficin IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Screen - DTT/AET IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Selected Cell Screen - Chlorquine/EGA IAT | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Thermal Amplitude Study | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Transfusion Related Acute Lung Injury (TRALI) Workup | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 | |||||
| Weak RhD Analysis | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 1 | 1 |
MISC ESTIMATED TOTAL $ - 0 $ - 0 $ - 0 $ - 0 $ - 0
File details come from the government source that posted it. Updated .